

## Financial Tear Sheet


### Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

### Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$190.49
Change (%)	▼ 1.27 (0.66%)
Volume	2,320,837
52 Week Low	\$163.31
Market Cap	\$126,048,377,273
Rolling EPS	3.15
PE Ratio	60.473
Shares Outstanding	661,706,007



Data as of 07/20/18 4:00 p.m. ET

## Recent Headlines

07/19/18

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

07/18/18

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

07/12/18


Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

## Upcoming Events

DATE	TITLE
07/26/18 5:00 p.m. ET	Q2 2018 Amgen Earnings Conference Call

## Analyst Estimates / Ratings

Mean Recommendation: **2.3**



Unable to fulfill request.

## SEC Filings

FILING DATE	FORM
07/16/18	4
06/25/18	4
06/20/18	3
06/18/18	11-K

## Financial Reports

Q4 2017 Financial Results

## Presentations

05/21/18 Amgen Investor Insights Newsletter  
Q1 2018

*Data provided by Nasdaq. Minimum 15 minutes delayed.*